Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
- GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer March 13, 2026
Low-Dose Abiraterone Acetate: Phase 1 Trial Looks Very Promising
/in Clinical Trial, Metastatic, Phase 1/by MaxTaiwanese Study Uncovers Cancer-Fighting Potential of Common Allergy Drug
/in Drug repurposing, Preclinical Research/by MaxSummary of the PC-BETS Substudy C: Darolutamide in Biomarker-Selected mCRPC
/in Clinical Trial, Metastatic, Phase 2/by MaxFinal Data From Phase 3 PSMAfore Trial About 177Lu-PSMA-617 (Pluvicto)
/in Clinical Trial, Metastatic, Phase 3/by MaxEuropean Commission Approves Darolutamide Plus ADT for Metastatic Hormone-Sensitive Prostate Cancer
/in FDA approvals/by MaxThe European Commission has granted marketing authorization to darolutamide (Nubeqa) combined with androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). This approval, following a positive opinion from the European Medicines Agency in June 2025, allows darolutamide plus ADT to be used with or without docetaxel, offering clinicians greater flexibility in tailoring treatment. […]
Fracture Risk in Prostate Cancer: Insights from a STAMPEDE Trial Analysis on ADT and Zoledronic Acid
/in Retrospective studies/by MaxUpdate About PSMAddition Phase 3 Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxCRISPR: Gene Breakthrough Could Starve Cancer Cells of Vitamin D
/in CRISPR, Preclinical Research/by Max